• <noscript id="yywya"><kbd id="yywya"></kbd></noscript>
  • 發布時間:2019-07-29 22:25 原文鏈接: SitedirectedMutagenesisusingPCR

    Site-directed Mutagenesis using PCR

    Michael P. Weiner, Tim Gackstetter, Gina L. Costa, John C. Bauer, and Keith A. Kretz



    From: Molecular Biology: Current Innovations and Future Trends. Eds. A.M. Griffin and H.G.Griffin. ISBN 1-898486-01-8 1995 Horizon Scientific Press, PO Box 1, Wymondham, Norfolk, U.K. 


    In vitro site-directed mutagenesis is an invaluable technique for studying protein structure-function relationships, gene expression and vector modification. Several methods have appeared in the literature, but many of these methods require single-stranded DNA as the template. The reason for this, historically, has been the need for separating the complementary strands to prevent reannealing. Use of PCR in site-directed mutagenesis accomplishes strand separation by using a denaturing step to separate the complementing strands and allowing efficient polymerization of the PCR primers. PCR site-directed methods thus allow site-specific mutations to be incorporated in virtually any double-stranded plasmid; eliminating the need for M13-based vectors or single-stranded rescue.

    Several points should be mentioned concerning site-directed mutagenesis using PCR. First, it is often desirable to reduce the number of cycles during PCR when performing PCR-based site-directed mutagenesis to prevent clonal expansion of any (undesired) second-site mutations. Limited cycling which would result in reduced product yield, is offset by increasing the starting template concentration. Second, a selection must be used to reduce the number of parental molecules coming through the reaction. Third, in order to use a single PCR primer set, it is desirable to optimize the long PCR method. And fourth, because of the extendase activity of some thermostable polymerases it is often necessary to incorporate an end-polishing step into the procedure prior to end-to-end ligation of the PCR-generated product containing the incorporated mutations in one or both PCR primers.

    A protocol is provided as a facile method for site-directed mutagenesis and accomplishes the above desired features by the incorporation of the following steps: (i) increasing template concentration approximately 1000-fold over conventional PCR conditions; (ii) reducing the number of cycles from 25-30 to 5-10; (iii) adding the restriction endonuclease DpnI (recognition target sequence: 5-Gm6ATC-3, where the A residue is methylated) to select against parental DNA (note: DNA isolated from almost all common strains of E. coli is Dam-methylated at the sequence 5-GATC-3); (iv) using Taq Extender in the PCR mix for increased reliability for PCR to 10 kb; (v) using Pfu DNA polymerase to polish the ends of the PCR product, and (vi) efficient intramolecular ligation in the presence of T4 DNA ligase.

    Protocol. PCR-based Site Directed Mutagenesis

    • Plasmid template DNA (approximately 0.5 pmole) is added to a PCR cocktail containing, in 25 ul of 1x mutagenesis buffer: (20 mM Tris HCl, pH 7.5; 8 mM MgCl2; 40 ug/ml BSA); 12-20 pmole of each primer (one of which must contain a 5-prime phosphate), 250 uM each dNTP, 2.5 U Taq DNA polymerase, 2.5 U ofTaq Extender (Stratagene).

    • The PCR cycling parameters are 1 cycle of: 4 min at 94 C, 2 min at 50 C and 2 min at 72 C; followed by 5-10 cycles of 1 min at 94 C, 2 min at 54 C and 1 min at 72 C (step 1).

    • The parental template DNA and the linear, mutagenesis-primer incorporating newly synthesized DNA are treated with DpnI (10 U) and Pfu DNA polymerase (2.5U). This results in the DpnI digestion of the in vivo methylated parental template and hybrid DNA and the removal, by Pfu DNA polymerase, of the TaqDNA polymerase-extended base(s) on the linear PCR product.

    • The reaction is incubated at 37 C for 30 min and then transferred to 72 C for an additional 30 min (step 2).

    • Mutagenesis buffer (1x, 115 ul, containing 0.5 mM ATP) is added to the DpnI-digested, Pfu DNA polymerase-polished PCR products.

    • The solution is mixed and 10 ul is removed to a new microfuge tube and T4 DNA ligase (2-4 U) added.

    • The ligation is incubated for greater than 60 min at 37 C (step 3).

    • The treated solution is transformed into competent E. coli (step 4).


    相關文章

    羅氏診斷首款國產PCR一體機獲批

    1月5日,國家藥監局發布醫療器械批準證明文件,其中羅氏診斷產品(蘇州)有限公司最新獲批一款全自動核酸提取及熒光PCR檢測系統(國械注準20253222730)。這是目前羅氏診斷獲批的首個國產PCR一體......

    4500萬+預算,海關總署75臺套儀器設備重新招標

    近日,海關總署物資裝備采購中心發布多則公告,分別就“海關總署2025年數字化攝影X射線系統采購項目(重新招標)”“海關總署2025年PCR儀采購項目(重新招標)”“海關總署2025年彩色多普勒超聲診斷......

    閃量科技全自動PCR分析系統列入國家重點研發計劃的醫療器械

    醫療器械優先審批申請審核結果公示(2025年第14號)依據原國家食品藥品監督管理總局《醫療器械優先審批程序》(總局公告2016年168號),對申請優先審批的醫療器械注冊申請進行審核,現將符合優先審批情......

    超6900萬元!海關總署最新一批液質、氣相、PCR等儀器中標出爐

    近日,海關總署陸續公布了一批分析儀器的采購項目中標結果,涵蓋氣相色譜儀、超高效液相色譜-三重四極桿質譜儀、波長色散X射線熒光光譜、PCR儀蛋白質測定儀、基因測序儀等多個領域,總中標金額高達6900余萬......

    伯樂公司通過戰略收購與平臺推出擴展四款數字PCR產品系列

    全球生命科學研究和臨床診斷產品領域的領導者伯樂實驗室有限公司(紐約證券交易所代碼:BIO和BIO.B)近日宣布推出四款新的微滴式數字PCR(ddPCR?)平臺。新推出的儀器包括伯樂公司的QXConti......

    醫療器械優先審批申請審核結果公示(2025年第6號)

    國家藥品監督管理局醫療器械技術審評中心發布醫療器械優先審批申請審核結果公示(2025年第6號),同意了蘇州淦江生物技術有限公司申請的運動神經元存活基因1(SMN1)檢測試劑盒(PCR-熒光探針熔解曲線......

    3280萬元華中農業大學大批儀器采購意向涉PCR、蛋白純化等

    近日,華中農業大學發布多個實驗室儀器設備政府采購意向,采購的產品包括:超高分辨多色快速成像系統、熒光定量PCR儀、顯微鏡、蛋白純化系統、分析天平、電泳儀、搖床、細胞破碎儀、核酸轉染系統、純水系統等,采......

    伯樂領投Geneoscopy公司完成1.05億美元的C輪融資

    Geneoscopy公司周三宣布已完成1.05億美元的C輪融資。此輪融資由伯樂實驗室領投,兩家公司在一份聯合聲明中表示,這筆資金將用于支持Geneoscopy公司無創結直腸癌篩查檢測的推出。參與此次融......

    9.5個億!伯樂收購PCR公司

    波蘭生命科學公司ScopeFluidics近日表示,在收到交易的最后一筆款項后,該公司最近敲定了以1.3億美元(約合9.5億元人民幣)的價格將其子公司CuriosityDiagnostics出售給Bi......

    北京市聚合酶鏈反應(PCR)檢驗實驗室檢查指南(2024版)

    京藥監發〔2024〕261號各區市場監管局,房山區燕山市場監管分局,市市場監管局機場分局,經開區商務金融局,市藥監局各分局,各相關事業單位:為深入貫徹落實醫療器械生產監管相關法規要求,進一步規范北京市......

  • <noscript id="yywya"><kbd id="yywya"></kbd></noscript>
  • 东京热 下载